科研动态PubMed 摘要

冠状动脉疾病中的药物涂层球囊:比较西罗莫司与紫杉醇涂层技术的荟萃分析。

PubMed 学科轮询 · 2026-10-22

完整摘要 · 中文译文

背景与目的:药物涂层球囊(DCB)是冠状动脉介入治疗中药物洗脱支架的关键替代方案,其优势在于可实现药物递送而无需永久性植入物。紫杉醇涂层球囊(PCB)和西罗莫司涂层球囊(SCB)均是重要的治疗选择。本系统评价与荟萃分析旨在比较西罗莫司涂层球囊导管与紫杉醇涂层球囊导管在冠状动脉疾病患者中的疗效与安全性。 方法:我们按照PRISMA指南进行了系统评价与荟萃分析,检索了五个数据库。我们仅纳入随机对照试验(RCT)。使用固定效应或随机效应模型计算风险比(RR)和均数差(MD)及其95%置信区间,并在存在异质性时进行敏感性分析。 结果:共纳入8项试验,涉及1043例患者。荟萃分析显示,SCB与PCB在晚期管腔丢失方面无显著差异(MD 0.06,95% CI [-0.02至0.14])。仅有两项结局显示出有利于PCB的统计学显著差异:减少晚期管腔扩大(RR 0.66,95% CI [0.49-0.87],P = 0.004),以及在敏感性分析后,降低原发病变的二元再狭窄率。结论:本荟萃分析显示,SCB与PCB在冠状动脉介入治疗中具有相似的安全性和有效性,大多数结局无显著差异。然而,PCB在晚期管腔扩大和原发病变二元再狭窄率方面优于SCB。西罗莫司不同制剂之间相似的结局表明,其他因素影响成功 两者(药物涂层球囊)均安全有效,尽管PCB在特定情形下可能保留某些优势。仍需更大规模、更长期的研究来确定针对不同患者人群的最佳药物涂层球囊策略。 临床试验编号:不适用。

完整摘要 · 英文原文

BACKGROUND AND AIM: Drug-coated balloons (DCBs) are a key alternative to drug-eluting stents for coronary artery interventions, offering the advantage of drug delivery without permanent implants. Both paclitaxel-coated balloons (PCBs) and sirolimus-coated balloons (SCBs) are valuable treatment options. This systematic review and meta-analysis compare the efficacy and safety of sirolimus-coated versus paclitaxel-coated balloon catheters in patients with coronary artery disease. METHODS: We conducted a systematic review and meta-analysis following PRISMA guidelines, searching five databases. We exclusively included RCTs. Risk ratios (RR) and mean differences (MD) with 95% confidence intervals were calculated using fixed-effects or random-effects models, with sensitivity analysis performed in cases of heterogeneity. RESULTS: Eight trials involving 1043 patients were included. The meta-analysis demonstrated no significant difference between SCB and PCB for late lumen loss (MD 0.06, 95% CI [-0.02 to 0.14]). Only two outcomes showed statistically significant differences favoring PCB: reducing late lumen enlargement (RR 0.66, 95% CI [0.49-0.87], P = 0.004) and, after sensitivity analysis, lowering binary restenosis rates in de novo lesions CONCLUSION: This meta-analysis shows SCB and PCB have similar safety and efficacy in coronary artery interventions, with no significant differences in most outcomes. However, PCB outperforms late lumen enlargement and binary restenosis rates in de novo lesions. Similar outcomes across sirolimus formulations indicate other factors influence success. Both balloon types appear safe and effective, though PCB may retain certain advantages in specific scenarios. Larger, longer-term studies are needed to establish the optimal drug-coated balloon strategy for different patient populations. CLINICAL TRIAL NUMBER: not applicable.

English
Drug-coated balloons in coronary disease: meta-analysis comparing sirolimus- and paclitaxel-coated technologies.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界